読み込み中
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
通常取引
$40.4523
−$0.9477 · -2.29%
日中の時刻はETです。市場データは遅延する場合があります。
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
日中レンジ
現在 $40.4523
52週レンジ
現在 $40.4523
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
39
割高
センチメント
67
強気
リスク
35
中程度のリスク
モメンタム
72
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
日中レンジ
現在 $40.4523
52週レンジ
現在 $40.4523
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 226.6万 USD | — | — | — | — |
| 粗利益 | −226.6万 USD | — | — | — | — |
| 研究開発 | 1.51億 USD | 1.27億 USD | 9090.5万 USD | 5403.2万 USD | 3218.9万 USD |
| 販売・一般管理 | 4001.7万 USD | 3186.6万 USD | 2345.2万 USD | 1762.6万 USD | 1102.6万 USD |
| 営業費用 | 1.89億 USD | 1.59億 USD | 1.14億 USD | 7165.8万 USD | 4321.5万 USD |
| 受取利息 | 2361.1万 USD | 2501.9万 USD | 1419.4万 USD | 266.4万 USD | 40.2万 USD |
| 支払利息 | — | — | — | 401.8万 USD | — |
| 減価償却費と償却費 | 226.6万 USD | 229万 USD | 173.2万 USD | 53.8万 USD | 27.2万 USD |
| 営業利益 | −1.91億 USD | −1.59億 USD | −1.14億 USD | −7165.8万 USD | −4321.5万 USD |
| 純利益 | −1.68億 USD | −1.34億 USD | −1億 USD | −6764万 USD | −4281.3万 USD |
会社概要が更新されました 2026年10月5日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1.22億0.01%2.3兆 USD0.03%$380.78+0.74%
iShares Russell 2000 ETFIWM7749.21万0.10%790.26億 USD0.19%$283.25+0.61%
Vanguard Extended Market ETFVXF3656.63万0.04%954億 USD0.05%$237.44+0.89%
iShares Russell 2000 Growth ETFIWO2776.78万0.19%142.94億 USD0.24%$363.48+0.73%
iShares Biotechnology ETFIBB2540.92万0.24%105.49億 USD0.44%$207.36+1.01%
Schwab U.S. Small-Cap ETFSCHA1754.23万0.08%219.94億 USD0.03%$33.265+0.65%
Vanguard Russell 2000 ETFVTWO1717.14万0.09%180億 USD0.06%$114.39+0.60%
iShares U.S. Pharmaceuticals ETFIHE1200.27万0.77%16.03億 USD0.37%$98.35-0.30%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOiShares U.S. Pharmaceuticals ETFIHEAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
